Dental Implants With a SLActive® vs. SLA® Surface
Launched by INSTITUT STRAUMANN AG · Nov 8, 2018
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
This is a prospective, single-blinded, randomized, paired sample, multi-center clinical study. Eight visits per patient are scheduled in this study. The final analysis will be conducted after all patients completed the 12-month visit.
The study devices are CE- (Conformité Européenne, meaning European Conformity) marked products and used within their intended use.
Two centers in Spain will participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • males and females, at least 18 years old
- • partially edentulous patients in need of two or more dental implants (canine to molars) placed in two different quadrants in healed sites (3 months post extraction)
- • subject must have voluntarily signed the informed consent, is willing and able to attend scheduled follow-up visits, and agrees that the encoded data will be collected and analyzed
- Exclusion Criteria:
- • any contraindications for oral surgical procedures
- • dental implant placement contraindicated according to Instructions for Use (IFU)
- • subjects with inadequate oral hygiene (FMPS ≥ 20%)
- • subjects who are currently heavy smokers (defined \>10 cigarettes per day or \>1 cigar per day) or who use chewing tobacco
- • subjects with drug or alcohol abuse
- • patients requiring soft tissue and bone grafting procedures
- • inadequate bone volume
- • severe bruxism or clenching habits
- • women who are pregnant or planning to become pregnant at any point during the study duration.
- • patients who have systemic factors that could interfere with the healing process of either bone or soft tissue or the osseointegration process (e.g. bone metabolism disturbances, uncontrolled diabetes mellitus, anticoagulation drugs/ hemorrhagic diatheses)
- • patients with local factors that could interfere with the healing process, such as untreated periodontal diseases, acute infection of implant site, temporomandibular joint disorders, treatable pathologic diseases of the jaw and changes in the oral mucosa)
- • conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability.
Trial Officials
Mariano Sanz, Prof. Dr.
Principal Investigator
Professor and Chairman of Periodontology
Juan Blanco-Carrión, Prof. Dr.
Principal Investigator
Professor in Periodontology
About Institut Straumann Ag
Institut Straumann AG is a leading global provider of dental implant solutions and restorative dentistry, committed to advancing oral health through innovative technologies and comprehensive solutions. With a strong emphasis on research and development, the company is dedicated to enhancing patient outcomes by delivering high-quality products and services that meet the evolving needs of dental professionals. As a clinical trial sponsor, Institut Straumann AG focuses on rigorous scientific evaluation and collaboration with key stakeholders to ensure the safety and efficacy of its offerings, ultimately striving to set new standards in the field of dental care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Santiago De Compostela, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials